Home>CREON Patient Support>CFCareForward

CFCareForward Program

CFCareForward provides financial, nutritional, and educational support for patients with EPI due to cystic fibrosis (CF)

CFCareForward provides:

Prescription savings*
Nutritional supplements and multivitamins delivered at no charge^†
Access to informational and educational materials
Quick and easy enrollment at CFCareForwardEnrollment.com

Financial assistance programs may offer patients more
affordable treatment

Patients enrolled in CFCareForward co-pay will pay as little as $0 for CREON*

Copay Savings Card. — *Eligibility: Available to patients with commercial prescription insurance coverage for CREON who meet eligibility criteria. Copay assistance, vitamins and nutritional supplements, if any, are not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.

myAbbVie Assist provides medicines at no cost to qualified patients. Learn More.

A variety of products for nutritional and vitamin support
at every age^†

†For CFCareForward participants filling CREON prescriptions. Subject to availability.

Patient education resources and materials

Request patient starter kits,
product samples, and more

Contact a Rep

Determine an appropriate
per-meal dose for your patients

Use Dosing Guide

Indications and Important
Safety Information

Indications¹

CREON^® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
per meal (or greater than 10,000 lipase units/kg of body weight per day).
To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
CREON is not interchangeable with any other pancrelipase product.